Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.

Also called NCT02689362

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 146 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02689362
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02689362. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-08 (actual); primary completion 2018-08-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)
Acronym
EVOLUTION
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Evogliptin
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo Evogliptin
Intervention (Drug)
Placebo Sitagliptin
Lead sponsor
Eurofarma Laboratorios S.A. (class: industry)

Record details

Record id
cardio:ct-nct02689362
Content hash
03adf8f2412ad33d7b87ffc7f262095e9bacae5d3a097e3dfbb0b13cb6dce5b0